SCHEMBL598209

SCHEMBL598209

CC(C)(C)OCC(NC(=O)OCC1c2ccccc2-c2ccccc21)C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MDM4 O15151 2/20 0.56
TP53 P04637 2/20 0.56
CASP3 P42574 2/20 0.53
MDM2 Q00987 3/20 0.50
TLR2 O60603 2/20 0.50
TNF P01375 1/20 0.50
SLC17A5 Q9NRA2 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL119565 1.00 MDM4 (0.56) MDM4TP53CASP3MDM2TLR2
SCHEMBL30802551 1.00 MDM4 (0.56) MDM4TP53CASP3MDM2TLR2
SCHEMBL29367497 1.00 MDM4 (0.56) MDM4TP53CASP3MDM2TLR2
SCHEMBL29355082 1.00 MDM4 (0.56) MDM4TP53CASP3MDM2TLR2
SCHEMBL119575 1.00 MDM4 (0.56) MDM4TP53CASP3MDM2TLR2
SCHEMBL29624621 1.00 MDM4 (0.56) MDM4TP53CASP3MDM2TLR2
Fluoride SCHEMBL7155195 0.99 MDM4 (0.55) MDM4TP53CASP3MDM2TLR2
SCHEMBL30562127 0.96 MDM4 (0.53) MDM4TP53CASP3MDM2TLR2
SCHEMBL29400671 0.92 MDM4 (0.52) MDM4TP53CASP3MDM2TLR2
SCHEMBL9072218 0.91 MDM4 (0.50) MDM4TP53CASP3MDM2TLR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119192295-A Neurostatin cyclic peptide and preparation method and application thereof 西北师范大学 2024-12-27 CN claimed
CN-118873460-A Preparation method of antioxidant face cream 江西御美化妆品有限公司 2024-11-01 CN claimed
CN-117924414-A Compound for promoting Abeta clearance and preparation method and application thereof 中山大学 2024-04-26 CN claimed
CN-114380880-B Fmoc-amino acid modified 20 (S) -protopanoxadiol derivative and preparation method and application thereof 吉林大学 2023-06-23 CN claimed
CN-115232195-A Oligopeptide two-dimensional nanomaterial and application thereof 忻州师范学院 2022-10-25 CN claimed
CN-109265370-A Preparation method of N- (9-fluorenylmethoxycarbonyl) -O-tert-butyl-L-serine 四川什邡市三高生化实业有限公司 2019-01-25 CN claimed
EP-3966226-B1 MASP INHIBITORY COMPOUNDS AND USES THEREOF BAYER AG (DE) 2025-12-24 EP disclosed
US-12503491-B2 MASP inhibitory compounds and uses thereof BAYER AKTIENGESELLSCHAFT (DE) 2025-12-23 US disclosed
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-07-29 US disclosed
CN-120192365-A Colipase inhibiting peptide and application thereof 宜客美股份有限公司 2025-06-24 CN disclosed
US-20250197378-A1 SMALL MOLECULE MODULATORS OF IL-17 LEO PHARMA AS (DK) 2025-06-19 US disclosed
EP-4548937-A1 ANTIBODY-DRUG COMPLEX Eisai R&D Management Co., Ltd. (JP) 2025-05-07 EP disclosed
CN-119192295-A Neurostatin cyclic peptide and preparation method and application thereof 西北师范大学 2024-12-27 CN disclosed
US-20080004451-A1 Pseudo proline dipeptides HOFFMANN-LA ROCHE INC. 2008-01-03 US disclosed
WO-2008000641-A1 PSEUDO PROLINE DIPEPTIDES F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed
CN-1649625-A Conjugates of therapeutic or cytotoxic agents and biologically active peptides UNIV TULANE (US) 2005-08-03 CN disclosed
CN-1380883-A Novel derivatives and analogues of galanthamine SANOCHEMIA PHARMAZEUTIKA AG (AT) 2002-11-20 CN disclosed
EP-1140979-A1 POLYOL COMPOUNDS, THEIR PRODUCTION AND USE Takeda Chemical Industries, Ltd. (JP) 2001-10-10 EP disclosed
WO-2000040599-A1 POLYOL COMPOUNDS, THEIR PRODUCTION AND USE TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2000-07-13 WO disclosed
EP-0316495-A1 Synthetic peptides useful for the detection of aids-related antibodies in human sera IAF BIOCHEM INTERNATIONAL INC. (CA) 1989-05-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197378-A1 SMALL MOLECULE MODULATORS OF IL-17 IL17A, IL2, IL23R MDM4 2562/4885TP53 91/4885CASP3 721/4885
US-12503491-B2 MASP inhibitory compounds and uses thereof MASP2, SERPINB1, SPINT2 MDM4 2629/4885TP53 2648/4885CASP3 795/4885
US-20080004451-A1 Pseudo proline dipeptides PNISR, PTMS, ARGLU1 MDM4 1806/4885TP53 1245/4885CASP3 1921/4885
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action KRAS, NRAS, HRAS MDM4 441/4885TP53 34/4885CASP3 3906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.